Immunotherapy is a method of treating cancer that uses drugs to empower the immune system to recognize and fight cancer. MSK has been a pioneer in developing immunotherapy. The approach has proven very effective in treating advanced melanoma.

There are several forms of immunotherapy. The immunotherapy drugs most commonly used to treat melanoma are called checkpoint inhibitors. Checkpoint inhibitors work by unleashing T cells (immune cells that seek out and destroy tumors). This therapy is sometimes called immune checkpoint blockade because the molecule that acts as a natural brake on T cells the checkpoint is blocked by the drug, thereby releasing the brake. Three checkpoint inhibitor drugs are currently available to treat advanced melanoma. These are ipilimumab (Yervoy®), nivolumab (Opdivo®), and pembrolizumab (Keytruda®). Learn more about these drugs and MSK’s role in their development below. Nivolumab (Opdivo®) and pembrolizumab (Keytruda®) belong to a class of drugs called PD-1 blockers. Both of these medications work by inhibiting the molecule PD-1. These drugs have proven very effective against metastatic melanoma and stage III melanoma that cannot be removed completely with surgery. Even people with stage III melanoma that can be removed with surgery may potentially benefit from treatment with anti-PD-1 immunotherapy.

Kindly submit your manuscript at https://www.longdom.org/submissions/immunotherapy-open-access.html or you can mail through this mail id as an attachments immunother@emedsci.com 

Explore more information at Immunotherapy Open Access. You can share your experiences too by publishing your novel fact findings in this Journal.

Regards

Alex John
Immunotherapy Open Access
Editorial Manager     
E-mail id: immunotherapy@scholarlymed.com